Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label multicenter study of SHR2554 combinations in advanced gastric or gastroesophageal junction cancer
CTR20253019Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zeprumetostat in gastric cancer (GC), esophagogastric junction cancer, sponsored by Hengrui Therapeutics. Started Sep 2025; status: active.
02
Drugs
zeprumetostat
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on CTR20253019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253019.